☆ 4.3 Article

Assessing the duration of EDSS improvement after a therapy start: A novel approach applied to the long-term extension of the PRISMS study

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2023)

Related references

Note: Only part of the references are listed.

Article Clinical Neurology

Prevalence of disability improvement in relapsing-remitting multiple sclerosis patients treated with cladribine tablets

Alessio Signori et al.

Summary: This study demonstrates the application of the prevalence estimator of EDSS improvement in patients treated with cladribine tablets. The results show that cladribine tablets have a significantly higher prevalence of improvement compared to placebo at 2 years and 5 years. The prevalence estimator is found to be more powerful in assessing treatment effects over the long term compared to the cumulative incidence of improvement.

EUROPEAN JOURNAL OF NEUROLOGY (2022)

Add to Collection

Article Clinical Neurology

Prevalence of disability improvement as a potential outcome for multiple sclerosis trials

Alessio Signori et al.

Summary: This study proposes a new estimator for assessing and comparing the prevalence of improvement in MS patients, revealing a significant difference in improvement rates between relapsing-remitting and secondary-progressive patients after autologous hematopoietic stem cell transplantation. The findings highlight the relevance of this new estimator in trials evaluating drugs for neuroprotection or repair.

MULTIPLE SCLEROSIS JOURNAL (2021)

Add to Collection

Article Clinical Neurology